Clinical trials: Tree Nut Allergy
Peanut Allergy
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing…
- Trial name
- NCT03682770
- Testing
- Dupilumab, AR101
- Where
- 25 sites in United States
- Volunteers
- 148 people
- Sponsor
- Regeneron Pharmaceuticals
Food Allergy, Peanut Allergy
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
The primary objective of this study is to determine whether allowing ingestion of sub-threshold amounts of peanut in those with a high threshold (tolerate at least 143 mg peanut protein on supervised double-blind…
- Trial name
- CAFETERIA (NCT03907397)
- Testing
- Peanut Protein, Continued peanut avoidance
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Scott Sicherer
Peanut Allergy
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
- Trial name
- ARC001 (NCT01987817)
- Testing
- AR101 powder provided in capsules
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
The objectives of this open-label follow-up study for subjects who previously were randomized and have completed the VIPES study for the treatment of peanut allergy, are: To assess the efficacy of Viaskin Peanut after up to 36…
- Trial name
- OLFUS-VIPES (NCT01955109)
- Testing
- Viaskin Peanut 250 mcg
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 171 people
- Sponsor
- DBV Technologies
Food Hypersensitivity
Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study
Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed with peanut allergy by lowering the risk of…
- Trial name
- DEVIL (NCT00932828)
- Testing
- Peanut oral immunotherapy
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of North Carolina, Chapel Hill
Allergy, Peanut
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection…
- Trial name
- NCT04984876
- Testing
- ligelizumab
- Where
- 55 sites in United States, Australia and 8 more
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Peanut Allergy
Follow up of LEAP Participants and Their Families
This prospective, cross-sectional study was designed to improve understanding of how early-life introduction of peanuts may promote the maintenance of tolerance in adolescence and will serve as an additional safety evaluation of…
- Trial name
- NCT03546413
- Where
- United Kingdom
- Volunteers
- 1,868 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Peanut Allergic Subjects
Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour)
Many children who are allergic to peanuts do not outgrow their allergy and have very severe allergic reactions called anaphylaxis.
- Trial name
- PeanutFlour (NCT02203799)
- Testing
- Peanut Oral Immunotherapy (POIT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Peanut Hypersensitivity
Peanut Oral Immunotherapy in Children
This is a randomized, double-blind, placebo-controlled, multi-center study comparing peanut oral immunotherapy (OIT) to placebo in the induction of tolerance and desensitization in peanut-allergic children.
- Trial name
- IMPACT (NCT01867671)
- Testing
- Peanut Oral Immunotherapy - Liquid Extract, Peanut Oral Immunotherapy - Peanut Flour
- Where
- 5 sites in United States
- Volunteers
- 146 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Peanut Allergy, Multi-food Allergy
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew…
- Trial name
- OUtMATCH (NCT03881696)
- Testing
- Omalizumab, Multi-Allergen Oral Immunotherapy
- Where
- 10 sites in United States
- Volunteers
- 458 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Food Hypersensitivity, Hypersensitivity
A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial
The purpose of this study is to evaluate the safety and immune response to daily sublingual (under the tongue) immunotherapy (SLIT) with peanut extract in adults and children with peanut allergies.
- Conditions
- Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
- Trial name
- NCT00580606
- Testing
- Glycerinated peanut allergenic extract
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Peanut Hypersensitivity
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the…
- Trial name
- NCT00382148
- Testing
- omalizumab
- Volunteers
- 11 people
- Sponsor
- Genentech, Inc.
Peanut Allergy
Tolerance Following Peanut Oral Immunotherapy
The unifying objective of this project is to determine whether peanut oral immunotherapy (PN OIT) induced clinical tolerance in the context of food allergy is significantly associated with the expansion of a specific regulatory T…
- Trial name
- PNOIT2 (NCT01750879)
- Testing
- Peanut Flour, Oat Flour
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Massachusetts General Hospital
Peanut Hypersensitivity
Boiled Peanut Oral Immunotherapy
Prospective Phase 1 clinical trial providing proof of concept data on boiled peanut oral immunotherapy (OIT) for the treatment of peanut allergy in children.
- Trial name
- BPOIT (NCT04090203)
- Testing
- Boiled Peanut Powder
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alton Melton
Allergy;Food, Allergy to Shrimp
Food Allergen OIT for Shrimp and Cashew
A prospective Phase 2, single-center, single-allergen OIT of cashew or shrimp in participants with proven allergies to either cashew or shrimp, respectively.
- Conditions
- Allergy;Food, Allergy to Shrimp, Allergy to Cashew Nut (Disorder)
- Trial name
- MOTIF (NCT03504774)
- Testing
- Cashew or Shrimp Oral Immunotherapy
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Sayantani B. Sindher
Peanut Allergy
ARTEMIS Peanut Allergy In Children
The purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.
- Trial name
- ARTEMIS (NCT03201003)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 18 sites in France, Germany and 5 more
- Volunteers
- 175 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Hypersensitivity, Food Allergy
FARE Peanut SLIT and Early Tolerance Induction
Primary Objective: To determine if 36 months of peanut SLIT as an early intervention in subjects ages 1 to 4 years induces clinical desensitization.
- Conditions
- Peanut Hypersensitivity, Food Allergy, Food Hypersensitivity, Peanut Allergy
- Trial name
- FARE/SLIT (NCT02304991)
- Testing
- Liquid Peanut Extract
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of North Carolina, Chapel Hill
Hypersensitivity, Food Allergy
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
Food allergy is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15…
- Conditions
- Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity
- Trial name
- NCT03679676
- Testing
- Omalizumab, Dupilumab
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Stanford University
Peanut Allergy
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
- Trial name
- NCT02993107
- Testing
- AR101
- Where
- 65 sites in United States, Canada and 7 more
- Volunteers
- 388 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.
- Trial name
- PALISADE (NCT02635776)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 69 sites in United States, Canada and 8 more
- Volunteers
- 555 people
- Sponsor
- Aimmune Therapeutics, Inc.